Global Alliance for TB and Tibotec have enterned into a partnership to accelerate the discovery and development of new drugs for tuberculosis (TB).
The two organizations will share their expertise and resources in the development of TMC207.
Under the agreement, Tibotec will continue to develop TMC207 for the treatment of MDR-TB, and will establish an access program to ensure that the compound reaches developing countries.
The agreement grants the TB Alliance a royalty-free license for the worldwide development and access to TMC207 in the field of drug-susceptible TB.
In addition, Tibotec will collaborate with the TB Alliance on a discovery research program to identify new compounds for the treatment of TB. The rights for the newly discovered compounds for the treatment of tuberculosis, will belong to the TB Alliance under a royalty free license.
Paul Stoffels, Global Head of Pharmaceutical Research and Development, Johnson & Johnson, said: To make a meaningful contribution to the global fight against TB, we knew we had to take a novel approach. Our collaboration with the TB Alliance represents a major step forward in the fight against TB as the two organizations combine their expertise and resources in the quest to make new TB treatments available.